806
Participants
Start Date
March 31, 2002
Primary Completion Date
August 31, 2005
Study Completion Date
August 31, 2005
CEP-1347 10mg
CEP-1347 10mg, a K252a derivative, retains neuroprotective properties
CEP1347 25mg
CEP1347 25mg, a K252a derivative, retains neuroprotective properties
CEP-1347 50mg
CEP-1347 50mg, a K252a derivative, retains neuroprotective properties
Placebo Comparator
Placebo capsules matching the CEP-1347 capsules
Beth Israel Medical Center, Department of Neurology, New York
Columbia Presbyterian Medical Center, Neurological Institute, New York
Movement Disorders Center/North Shore - LIJ Health System, Manhasset
Long Island Jewish Medical Center, New Hyde Park
Parkinson's Disease & Movement Disorders Center of AMC, Albany
University of Rochester, Department of Neurology, Rochester
Pennsylvania Hospital/Dept. of Neurology, Philadelphia
University of Maryland, Baltimore
Johns Hopkins University, Department of Neurology, Baltimore
University of Virginia Health System/Adult Neurology, Charlottesville
Duke University Medical Center, Durham
Medical College of Georgia, Augusta
Davis Building - Neurology 8-B, Jacksonville
Cleveland Clinic Florida, Weston
University of South Florida, Harbourside Medical Tower, Tampa
University of Tennessee Memphis, Semmes Murphy Clinic, Memphis
Medical College of Ohio, Department of Neurology, Toledo
Cleveland Clinic Foundation, Cleveland
Indiana University of Medicine/Outpatient Clinical Research Facility, Indianapolis
Clinical Neuroscience Center, Southfield
University of Iowa Hospitals and Clinics, Department of Neurology, Iowa City
Medical College of Wisconsin, Department Neurology, Milwaukee
University of Minnesota, Department of Neurology, Minneapolis
Northwestern University, Department of Neurology, Chicago
Rush-Presbyterian-St. Luke's Medical Center, Chicago
University of Chicago, Chicago
Washington University, St Louis
University of Kansas Medical Center/Dept. of Neurology, Kansas City
Creighton University/Department of Neurology, Omaha
LSUHSC in Shreveport, Shreveport
University of Arkansas for Medical Services, Little Rock
Scott and White Clinic/Texas A & M University, Temple
Parkinson's Disease Center and Movement Disorders Clinic/Baylor College of Medicine, Houston
Colorado Neurological Institute/Movement Disorders Center, Englewood
University of Colorado Health Sciences Center, Denver
Barrow Neurological Institute, Phoenix
Mayo Clinic Arizona, Scottsdale
University of California San Diego, San Diego
The Parkinson's and Movement Disorders Institute, Fountain Valley
California Medical Clinic for Movement Disorders, Oxnard
The Parkinson's Institute, Sunnyvale
Stanford University Medical Center, Dept. of Neurology, Stanford
Department of Neurology - UC Davis Medical Center, Sacramento
University of California Irvine, Irvine
USC, Keck School of Pharmacy, Department of Neurology, Los Angeles
University of Connecticut Health Center, Farmington
Institute for Neurodegenerative Disorders, New Haven
Center for Aging, Genetics and Neurodegeneration, Massachusetts General Hospital, Boston
Brigham and Womens Hospital/Neurology, Boston
Boston University Medical Center, Department of Neurology, Boston
Beth Israel Deaconess Medical Center, Boston
UMDNJ Robert Wood Johnson Medical Center, New Brunswick
University of Medicine and Dentistry of New Jersey/Center for Aging, Stratford
University of Cincinnati, Cincinnati
Oregon Health Sciences University/Dept. of Neurology, Portland
Brown University/Memorial Hospital of Rhode Island/Neurology Dept., Pawtucket
University of Calgary, Calgary
University of Alberta - Glenrose Rehab Hospital, Edmonton
London Health Sciences Center - University Campus, London
Ottawa Hospital, Civic Site, Ottawa
Toronto Hospital Western Division, Toronto
University of Sherbrooke, Fleurimont
Centre Hospitalier De L'Universite Montreal, Montreal
McGill Center for Studies in Aging, Verdun
Saskatoon District Health Board - Royal University Hospital, Saskatoon
University of Puerto Rico, Clinical Research Center, San Juan
Lead Sponsor
H. Lundbeck A/S
INDUSTRY
The Parkinson Study Group
NETWORK
Cephalon
INDUSTRY